GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AV-001 overview

AV-001 is under development for the treatment of pathogen-induced acute respiratory distress syndrome (ARDS), acute kidney injury, acute lung injury, sepsis, vascular dementia, ischemic stroke, covid-19 associated acute respiratory distress syndrome, lethal influenza and pneumococcal pneumonia, diabetic atherosclerosis, COVID-19 and metastatic disease. It is administered through intravenous bolus, parenteral route. It is a predecessor analog of vasculotide. Vasculotide is an angiogenic peptide mimetic and acts by targeting Tie-2.

It was also under development for the treatment of neuropathic diabetic foot ulcers, neuroischemic diabetic foot ulcers, diabetic wound healing, asthma, atopic dermatitis.

Vasomune Therapeutics overview

Vasomune Therapeutics is a biotechnology company developing the next generation of medications to harness the body’s ability to defend against illness by modifying cellular response for the treatment of patients with pathogen-induced Acute Respiratory Distress Syndrome.

For a complete picture of AV-001’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.